Trossman, Jeff rey C.
Blake, Cassels
& Graydon LLP
(416) 863-4290
jeff rey.trossman@
blakes.com
Mr. Trossman focuses
on income tax planning,
M&A, international tax
and reorganizations. He
acts for public and private
companies, represents
taxpayers at all levels of
the tax-appeal process and
serves as an offi cer of the
Canadian Bar Association.
Turner, John S.M.
Fasken Martineau
DuMoulin LLP
(416) 865-4380
jturner@fasken.com
As a leading M&A,
corporate fi nance and
"dirt lawyer," Mr. Turner's
expertise is sought in top
resource deals and in other
sectors. His clients include
issuers and underwriters in
Canada and throughout
Africa, Latin America
and Eastern Europe.
Urbani, Michael G.
Stikeman Elliott LLP
(604) 631-1340
murbani@stikeman.com
Mr. Urbani acts for private
and public entities and
investment dealers in
public fi nancings and
private placements, as well
as hostile and negotiated
take-over bids and M&As
involving public and
private corporations.
Turcotte, Maxime
Stikeman Elliott LLP
(514) 397-2421
mturcotte@stikeman.com
Mr. Turcotte specializes
in providing corporate
and securities law advice
(o en with a cross-
border or international
component) in corporate
fi nance transactions,
public and private M&A,
and project fi nancings.
Ulmer, John M.
Davies Ward Phillips
& Vineberg LLP
(416) 863-5505
julmer@dwpv.com
Mr. Ulmer focuses on tax
aspects of international
ventures, corporate fi nance
and real estate transactions.
A specialist in taxation of
REITS and cross-border real
estate investments, he advises
investors on acquisitions in
Canada, the US and abroad.
Vail, QC, Walter D.
Cox & Palmer
(506) 453-9602
wvail@coxandpalmer.com
Walter practises corporate
commercial, insolvency,
banking and property law,
acting for local, national and
international clients. He is
a member of CBA, ABA,
Insolvency Institute Canada
and Atlantic Provinces
Mediation Institute.
entitled each former shareholder of Vir-
ginia to receive 0.92 of a share of Osisko
for each share of Virginia held.
As a result of the transaction, Osisko
immediately became an intermediate gold
royalty and exploration company with two
world-class royalties on producing gold
mines in Québec, as well as exploration
stage assets.
Bennett Jones LLP represented Osis-
ko in the transaction with support of in-
house counsel André Le Bel, with a team
led by Sander Grieve, Linda Misetich
Dann and John Sabine (mining, M&A
and securities) that included Ian Gold-
berg, Jeff rey Kerbel, Jamie Au, Andrew
Disipio and Ian Minz (mining, M&A and
securities); ! omas Bauer, Martin Soren-
son, Philip Ward and Andrew Sullivan
(tax); and Randal Hughes and Adam Kal-
bfl eisch (competition).
Marc Pothier of XploraMines S.A
and McCarthy Tétrault LLP jointly rep-
resented Virginia in the transaction, with
a team led by Philippe Leclerc (M&A and
securities) that included Max Rogan and
Myreille Gilbert (M&A and securities);
François Amyot (contract matters) Annie
Mailhot-Gamelin and Christian Meighen
(tax); Dominic ! érien (competition) and
Jean Lortie (litigation).
Lavery, de Billy, L.L.P. represented
Osisko in Québec in the transaction, with
a team led by René Branchaud and Josia-
nne Beaudry (securities).
Skadden, Arps, Slate, Meagher &
Flom LLP represented Osisko in the
United States in the transaction, with a
team led by Christopher Morgan (corpo-
rate) and Jared Binstock (tax).
Burns & Levinson LLP represented
Virginia in United States securities mat-
ters in the transaction. ! e Burns & Levin-
son team was led by Andrew Merken (se-
curities) and Roy Gillig (tax).
TEKMIRA PHARMACEUTICALS
AND ONCORE BIOPHARMA
COMPLETE MERGER
Closing date: March 4, 2015 Tekmira Phar-
maceuticals Corporation (Tekmira) com-
pleted a merger of equals with OnCore Bi-
opharma, Inc. (OnCore) whereby OnCore
merged with a wholly owned subsidiary of
Tekmira. As a result of the merger, stock-
holders of OnCore hold approximately
fi y per cent (50%) of the total number
of outstanding shares of capital stock of
Tekmira. ! e implied market value of the
combined company, based on the closing
price of Tekmira common shares on the
NASDAQ Global Market on January 9,
2015, was approximately US$750 million
and at time of closing US$964 million.
! e merger of Tekmira, a leading de-
veloper of RNA interference therapeutics,
and OnCore, a biopharmaceutical com-
pany dedicated to discovering, developing
and commercializing an all-oral cure for
patients suff ering from chronic hepatitis
B virus (HBV) infection, will create a new
leading global HBV company focused on
developing a curative regimen for hepatitis
B patients by combining multiple thera-
peutic approaches.
Tekmira was represented by Farris,
Vaughan, Wills & Murphy LLP, with a
team led by Hector Mackay-Dunn, QC,
and including Ronald Murray, Peter Roth,
Denise Nawata, Melissa Mitchell and
Allan McGavin (corporate and securi-
ties); Ronald Chin (life science transac-
tions); David Selley (competition and
Investment Canada); Marylee Davies
(employment); Teresa Tomchak (securi-
ties regulatory) and ! om Ciz (tax); and
by US counsel Dorsey & Whitney LLP,
with a team led by Dan Miller and includ-
ing Parker Schweich, Jason Wisniewski
and Kyle Leingang (corporate and secu-
rities); John Hollirnake and John Chase
(tax); Michael Lindsay (anti-trust); Mi-
chael Voves (employee benefi ts); and Jes-
sica Linehan (employment).
OnCore was represented by Cooley
LLP, with a team led by Frank Rahmani,
and including Div Gupta, Brian Leaf,
Alison Haggerty, Mark Ballantyne and
Bobby Pratt (corporate and securities);
Jennifer Fonner Fitchen and Anne Lieber-
man (M&A); Marya Postner and Jennifer
LEXPERT
®
RANKED LAWYERS
36
|
BIG DEALS
